ArticleFrontiers in immunology2026
Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: About 30% of patients with phospholipase A2 receptor (PLA2R) associated membranous nephropathy (MN) have negative circulating anti-PLA2R antibodies. We investigated whether these patients harbor antibodies against linear PLA2R peptides, with the aim of improving serological detection. Methods: We synthesized 123 sequential overlapping linear peptides spanning the extracellular region of PLA2R across ten domains. Circulating IgG antibodies to these peptides were measured by ELISA in 42 biopsy-proven PLA2R-associated MN patients with negative circulating anti-PLA2R antibodies. Results: Twenty-six of 42 (61.9%) anti-PLA2R-negative MN patients reacted with at least one PLA2R peptide. Overall, 68 of 123 (55.3%) peptides were recognized, with the highest recognition frequencies for CysR-11 (21.4%), CTLD7-1 (14.3%) and CTLD7-2 (16.7%). Reactivity to these peptides was rare in patients with minimal change disease, focal segmental glomerulosclerosis, IgA nephropathy, hepatitis B virus-associated MN, or tumor-associated MN. Combined any positivity of antibodies to the three peptides yielded a sensitivity of 43.7% and a specificity of 81.3% for identifying PLA2R-associated MN in the absence of circulating anti-PLA2R antibodies. In inhibition assays, none of the three peptides detectably blocked binding of circulating anti-PLA2R antibodies to full-length PLA2R under the experimental conditions used. Among 32 anti-PLA2R-positive MN patients, 28 (87.5%) also reacted with PLA2R peptides, with frequent recognition of CysR-5, CTLD1-7, CTLD4-7, CTLD5-6, CTLD5-9, CTLD6-2, and CTLD7-2. Conclusions: Antibodies to linear PLA2R peptides are detectable in a substantial proportion of PLA2R-associated MN patients who are seronegative by conventional anti-PLA2R assays. CysR-11, CTLD7-1, and CTLD7-2 may serve as exploratory candidate biomarkers, and their pathogenic relevance warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.